Overview

Every second counts for those waiting for life-saving treatments. But the path from scientific discovery to patient access is long, complex, and filled with challenges. That's where WuXi AppTec's CRDMO platform makes a difference.

Beyond combining CRO, CDMO, and CMO services into a single platform, the CRDMO model streamlines the end-to-end drug development journey – seamlessly from early discovery to commercial manufacturing. Integrating expertise from three business segments, WuXi Chemistry, WuXi Biology, and WuXi Testing, this model eliminates handoffs and reduces delays, while ensuring unwavering quality – empowering innovators to move faster, lower costs, and improve the likelihood of success.

As a pharma and biotech CRDMO partner, WuXi AppTec's strategy is clear: follow the science, follow the customers, and follow the molecules. This is the essence of the model, enabling us to stay at the forefront of the industry and deliver value to our customers, bringing hope for patients in need.

Integrated Research: Earlier, Faster, Expand

With the increasing size and complexity of today's drug molecules, moving a novel molecule toward the next value-creation milestone like IND could be daunting, especially for biotech startups with only a handful of scientists and limited time and funding.

The CRDMO model begins with the integrated research platform. The three business segments collaborate seamlessly in a relay-like manner, enabling innovation from early drug discovery through preclinical and IND stages.

As a diverse array of new modalities continue to emerge, WuXi AppTec has always taken proactive steps to expand not just capabilities, but integrated solutions. The influx of innovative projects at early stage enables us to understand the innovative R&D trends, embarking on forward-looking preparations. More than a service provider, we act as a problem-solver, and a strategic and trusted partner: sharing our know-how, expertise and offering well-prepared, comprehensive solutions. In doing so, innovators can focus on scientific breakthroughs while leveraging CRDMO's depth in drug research and development (R&D) to improve efficiency, rather than building infrastructure from scratch.

With strong synergy across multiple business units, the integrated research platform ensures seamless project transitions from upstream to downstream, reducing the risks associated with drug project transitions, speeding up progress, and lowering costs.

Development And Manufacturing: Powering Breakthroughs at Every Stage

Drawing upon the early-stage drug discovery foundation, the CRDMO model also gains early insights into industry development opportunities, allowing us to plan capacity construction in advance to meet the evolving needs from global innovators.

Our combined development and manufacturing (D+M) services further empower early-stage innovators with comprehensive infrastructure, expertise, and technology needed to advance their pipeline at scale. With rapidly expanding capacity – spanning manufacturing of API, small molecules, peptides, oligonucleotides, and more - we are always ready to deliver when the demand for large-scale production rises.

Built on this foundation, WuXi AppTec's CRDMO model acts as a catalyst for healthcare innovation, seamlessly managing every stage from drug discovery to delivery. From small molecules, to emerging modalities, we are able to support all those transformative medicines that hold the promise to improve lives. Across oncology, immunology, neurological disorders, rare diseases, and many others, our efficiency translates directly to patients - faster access, more affordable treatments, and greater hope.

We're proud to work alongside our global partners to achieve the shared vision to build a future where "every drug can be made and every disease can be treated."